Skip to content

Petri Bono

University of Helsinki

1 paper in the Anchorcite directory, published in 2015, cited 5,913 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2015 · 5,913 citations

    BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell…

Metadata from OpenAlex (CC0).